NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.57 -0.13 (-4.81 %) (As of 11/20/2018 04:00 PM ET)Previous Close$2.70Today's Range$2.56 - $2.7352-Week Range$2.56 - $5.98Volume1.10 million shsAverage Volume1.10 million shsMarket Capitalization$303.03 millionP/E Ratio-2.92Dividend YieldN/ABeta2.46 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts. Receive KERX News and Ratings via Email Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:KERX Previous Symbol CUSIP49251510 Webwww.keryx.com Phone617-466-3500 Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.19 Price-To-Earnings Trailing P/E Ratio-2.92 Forward P/E Ratio-4.36 P/E GrowthN/A Sales & Book Value Annual Sales$60.64 million Price / Sales4.34 Cash FlowN/A Price / CashN/A Book Value($0.12) per share Price / Book-21.42 Profitability EPS (Most Recent Fiscal Year)($0.88) Net Income$-163,440,000.00 Net Margins-96.41% Return on EquityN/A Return on Assets-60.05% Miscellaneous Employees210 Outstanding Shares102,380,000Market Cap$303.03 million OptionableOptionable Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions What is Keryx Biopharmaceuticals' stock symbol? Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX." How were Keryx Biopharmaceuticals' earnings last quarter? Keryx Biopharmaceuticals (NASDAQ:KERX) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analysts' expectations of $29.56 million. View Keryx Biopharmaceuticals' Earnings History. When is Keryx Biopharmaceuticals' next earnings date? Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Keryx Biopharmaceuticals. What price target have analysts set for KERX? 6 equities research analysts have issued 1-year price objectives for Keryx Biopharmaceuticals' stock. Their predictions range from $4.00 to $9.00. On average, they anticipate Keryx Biopharmaceuticals' share price to reach $6.60 in the next twelve months. This suggests a possible upside of 156.8% from the stock's current price. View Analyst Price Targets for Keryx Biopharmaceuticals. What is the consensus analysts' recommendation for Keryx Biopharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keryx Biopharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Keryx Biopharmaceuticals. What are Wall Street analysts saying about Keryx Biopharmaceuticals stock? Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock: 1. HC Wainwright analysts commented, "Valuation compelling. Keryx stock price has pulled back since the merger was announced in June, losing 33% of its value versus the XBI Biotech index losing only 9%. However we see only improving fundamentals as Auryxia revenues continue to improve QoQ." (11/9/2018) 2. Maxim Group analysts commented, "Keryx reported 3Q18 with total revenue of $28.0M, a slight miss from the consensus estimate of $29.1M. US Auryxia sales for the quarter were $26.6M up 11% q/q, driven by increased RX volume. The company reported a net loss of ($17.0M) and ended the quarter with $41.1M in cash." (11/9/2018) 3. According to Zacks Investment Research, "Keryx is completely dependent on Auryxia for growth as it is the only approved product in the company’s portfolio. Auryxia faces stiff competition in the United States from existing players. Shares of the company have underperformed the industry so far this year. However, Keryx's launch of Auryxia for the second indication — iron deficiency anemia (IDA) in chronic kidney disease patients — is boosting sales of the company, given that the IDA market holds great potential. Keryx entered a definitive merger agreement with Akebia Therapeutics that will create a fully integrated company focused on the development and commercialization of therapeutics for patients with chronic kidney diseases. The combined company will be well positioned to create significant shareholder value and accelerate growth beyond what either company would achieve separately. Loss estimates have remained stable ahead of Q3 earnings release." (10/9/2018) Has Keryx Biopharmaceuticals been receiving favorable news coverage? News stories about KERX stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Keryx Biopharmaceuticals earned a news impact score of 1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Keryx Biopharmaceuticals' key competitors? Some companies that are related to Keryx Biopharmaceuticals include Uniqure (QURE), Wave Life Sciences (WVE), Arrowhead Pharmaceuticals (ARWR), TherapeuticsMD (TXMD), IMMURON Ltd/S (IMRN), Zai Lab (ZLAB), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Alder Biopharmaceuticals (ALDR), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA) and Clovis Oncology (CLVS). Who are Keryx Biopharmaceuticals' key executives? Keryx Biopharmaceuticals' management team includes the folowing people: Ms. Jodie Pope Morrison, Interim CEO & Director (Age 43)Mr. Scott A. Holmes, CFO, Sr. VP & Treasurer (Age 44)Ms. Christine A. Carberry, Sr. VP & COO (Age 57)Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)Mr. Tony Chambers, VP of Sales Who are Keryx Biopharmaceuticals' major shareholders? Keryx Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Abrams Capital Management L.P. (7.57%), BlackRock Inc. (5.98%), Rice Hall James & Associates LLC (1.85%), Bank of New York Mellon Corp (0.82%), FMR LLC (0.48%) and Morgan Stanley (0.41%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Christine A Carberry, Greg Madison, John F Neylan, Kevin J Cameron, Scott A Holmes and Steven C Gilman. View Institutional Ownership Trends for Keryx Biopharmaceuticals. Which institutional investors are selling Keryx Biopharmaceuticals stock? KERX stock was sold by a variety of institutional investors in the last quarter, including Abrams Capital Management L.P., Morgan Stanley, Bristol Advisors LLC, Bank of New York Mellon Corp, Rice Hall James & Associates LLC, Lincoln Capital Corp and Credit Suisse AG. Company insiders that have sold Keryx Biopharmaceuticals company stock in the last year include Brian Adams, Christine A Carberry, Greg Madison, John F Neylan, Kevin J Cameron, Scott A Holmes and Steven C Gilman. View Insider Buying and Selling for Keryx Biopharmaceuticals. Which institutional investors are buying Keryx Biopharmaceuticals stock? KERX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Nexthera Capital LP and Rubric Capital Management LP. View Insider Buying and Selling for Keryx Biopharmaceuticals. How do I buy shares of Keryx Biopharmaceuticals? Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Keryx Biopharmaceuticals' stock price today? One share of KERX stock can currently be purchased for approximately $2.57. How big of a company is Keryx Biopharmaceuticals? Keryx Biopharmaceuticals has a market capitalization of $303.03 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Keryx Biopharmaceuticals employs 210 workers across the globe. What is Keryx Biopharmaceuticals' official website? The official website for Keryx Biopharmaceuticals is http://www.keryx.com. How can I contact Keryx Biopharmaceuticals? Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected] MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 462 (Vote Outperform)Underperform Votes: 319 (Vote Underperform)Total Votes: 781MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What impact do institutional investors have on markets?